Premium
The role of blood services and regulatory bodies in stem cell transplantation
Author(s) -
Austin E. B.,
Guttridge M.,
Pamphilon D.,
Watt S. M.
Publication year - 2008
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2007.00974.x
Subject(s) - legislation , stem cell , transplantation , haematopoiesis , cord blood , government (linguistics) , procurement , medicine , hematopoietic stem cell transplantation , regenerative medicine , immunology , intensive care medicine , business , biology , political science , law , microbiology and biotechnology , linguistics , philosophy , marketing
Advances in stem cell research over the past few decades have coincided with large increases in haemopoietic stem cell transplantation (HSCT) using either bone marrow, peripheral blood or cord blood‐derived stem cells. Alongside this growth has come an increase in the role played by regulatory bodies, both governmental and professional, to ensure that those undertaking such procedures do so in a manner so as to minimize the risk to patients. Interestingly, government legislation encompasses not only cellular therapies, but also the use of tissues and organs, as many of the processes and procurement procedures involved are similar. In this review, we analyse the trends in HSCT, describe the development and impact of legislation within Europe on this practice and outline the vital role played by the UK blood services in providing robust and high‐quality HSCT services.